Positive interim efficacy data in 2025 underscore potential of ETX101 as a one-time, disease-modifying medicine for Dravet syndrome –– Internal GMP manufacturing capable of supporting pivotal trial ...

Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three ...

"Over the past decade, Uzbekistan’s economy has undergone an accelerated process of qualitative and systemic transformation." ...

While in the mid-2010s the country’s nominal gross domestic product stood at approximately USD 60-65 billion, it has now ...

IonQ’s investment thesis is neutral-to-bullish, supported by a full-stack platform strategy and a $1B-plus commercial ...

Seiga Ohmine to join as Chief Commercial Officer, Sharad Dubey as Chief Financial Officer and Patrick Lansky as Senior Vice ...

The mathematics protecting communications since before the internet remain our strongest defense against machine-speed ...

Q2 2026 Earnings Call Transcript January 6, 2026 AAR Corp. beats earnings expectations. Reported EPS is $1.18, expectations ...

Enthusiasts thought the discovery that graphene, a form of carbon, could be extracted from graphite would change the world.

Dosed First Patient in REVEAL Pivotal Trial in the Fourth Quarter of 2025. Additional enrollment continues to advance across ...

The current foreign policy of the United States, particularly after its withdrawal from the Paris Agreement for a second time ...

Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and StudiesAUSTIN, Texas, Jan.